173336-76-0

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Bromo-1-methoxy-2-(3-methoxy-propoxy)-benzene is used as a key intermediate in the synthesis of various pharmaceuticals for its unique chemical structure that can be further modified to create new drug molecules.
Used in Agrochemical Development:
In the agrochemical industry, 4-Bromo-1-methoxy-2-(3-methoxy-propoxy)-benzene is utilized as a building block for the development of new agrochemicals, potentially enhancing crop protection and yield.
Used in Organic Chemistry Research:
4-Bromo-1-methoxy-2-(3-methoxy-propoxy)-benzene serves as a valuable compound in organic chemistry research, where its unique structure can be explored for new reactions and the synthesis of novel organic compounds.
Used in Materials Science:
In the field of materials science, 4-Bromo-1-methoxy-2-(3-methoxy-propoxy)-benzene may be employed in the development of new materials, leveraging its chemical properties to create innovative products with specific applications.

InChI:InChI=1/C11H15BrO3/c1-13-6-3-7-15-11-8-9(12)4-5-10(11)14-2/h4-5,8H,3,6-7H2,1-2H3

Upstream product

• 36865-41-5 3-bromopropanol methyl ether 
• 37942-01-1 5-bromo-2-methoxyphenol 
• 36215-07-3 1-Chloro-3-methoxypropane 

Downstream Products

• 934841-22-2 C₃₀H₄₇NO₈ 
• 1024754-25-3 3-[4-methoxy-3-(3-methoxypropoxy)phenyl]prop-2-yn-1-ol 
• 1257529-92-2 (3S,5S)-5-((1S,3S)-1-Azido-3-(hydroxy(4-methoxy-3-(3-methoxypropoxy)phenyl)methyl)-4-methylpentyl)-3-isopropyldihydrofuran-2(3H)-one 
• 935847-26-0 (2S,7S,E)-2,7-diisopropyloct-4-enedioic acid 
• 1200341-29-2 (1R,2S)-2-isopropyl-1-(4-methoxy-3-(3-methoxypropoxy)phenyl)pent-4-en-1-ol 
• 878276-60-9 carbonic acid 2-tert-butoxycarbonylamino-4-[4-methoxy-3-(3-methoxypropoxy)benzoyl]-5-methylhexyl ester tert-butyl ester 
• 173334-57-1 (2S,4S,5S,7S)-5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide 
• 173338-07-3 tert-butyl (3S,5S,6S,8S)-8-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-6-hydroxy-3-(4-methoxy-3-(3-methoxypropoxy)benzyl)-2,9-dimethyldecan-5-ylcarbamate 
• 866030-35-5 tert-butyl {(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-3-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl}carbamate 
• 1236549-00-0 {(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxo-furanidin-2-yl)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-carbamic acid benzyl ester 
• 1236549-06-6 (1S,2S,4S)-4-(2-carbamoyl-2-methylpropyl-carbamoyl)-2-hydroxy-1-{(S)-2-[4-methoxy-3-(3-methoxypropoxy)-benzyl]-3-methylbutyl}-5-methylhexyl-carbamic acid benzyl ester 
• 1290075-65-8 C₃₂H₄₅NO₆ 
• 1027526-91-5 C₃₂H₄₅NO₇ 
• 1309922-65-3 (3S,5R)-5-((1R,3S)-1-Hydroxy-3-(4-methoxy-3-(methoxypropoxy)benzoyl)-4-methylpentyl)-3-isopropyl-dihydrofuran-2(3H)-one 

Relevant academic research and scientific papers

Development of DHQ-based chemical biology probe to profile cellular targets for HBV

Chronic hepatitis B virus (HBV) infection has been a serious public health burden worldwide. Current anti-HBV therapies could not eliminate HBV ultimately. Considering the characteristics of HBV, it is impossible to be entirely cured based on current therapies. Therefore, it is urgently needed to develop novel therapeutic agents with new mechanism of action. The dihydroquinolizinone (DHQ) derivatives exhibited potent anti-HBV activity by decreasing HBV DNA and HBsAg level in an obscure mechanism of action. In this study, we have optimized the DHQ scaffold, developed the photoaffinity probe, with which to identify potential binding proteins.

Compound with PDE4 inhibitory activity, preparation method, composition and application thereof

The invention belongs to the field of medicines, and particularly relates to a compound with PDE4 inhibitory activity, and a preparation method, composition and application thereof. The compound is acompound with a structure shown as a formula I or pharmaceutically acceptable salt thereof, in the formula, R1 represents N, N-dimethylaminoethyl, 3-amino-3-oxopropyl, 3, 3-difluoropropyl and methoxyalkyl, and R2 represents a cyano group, an aminosulfonyl group, an aminocarbonyl group or an alkyl acylamino group. The compound provided by the invention has good PDE4 inhibitory activity, has the advantages of high efficiency and low side effect, and can be used for preparing drugs for preventing and/or treating allergic diseases, autoimmune diseases or inflammatory diseases.

NOVEL OXA-AND AZA-TRICYCLIC 4-PYRIDONE-3-CARBOXYLIC ACID FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

Provided herein are oxa- and aza-tricyclic 4-pyridone-3-carboxylic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for inhibiting HBsAg secretion and HBV DNA production, and for treatment and/or prophylaxis of hepatitis B infection.

NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION

The disclosure includes compounds of Formula (I), wherein Z1, Z2, Z3, X, R1, R2, R3, R4, R5, R6, and R7 are defined herein. Also disclosed is a method for treating HBV infection.

Novel isoquinoline compound and medical application thereof

The invention relates to an isoquinoline compound shown as a formula (A) or a stereoisomer, a pharmaceutically acceptable salt, a hydrate, a solvate or a crystal thereof, a medicinal composition thereof and application thereof as antiviral medicines. The isoquinoline compound inhibits hepatitis B DNA activity and hepatitis B surface antigen activity at the same time. The invention particularly relates to application thereof to preparation of medicines for treating and/or preventing hepatitis B, hepatitis B viruses (HBV) thereof and other viral infectious diseases, in particular to treatment and/or prevention of the hepatitis B and the hepatitis B viruses as HBV Surface antigen inhibitor medicines and HBV DNA production inhibitor medicines.

PROCESS FOR THE PREPARATION OF (6S)-6-ALKYL-10-ALKOXY-9-(SUBSTITUTED ALKOXY)-2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID ANALOGUES

The present invention relates to a process for synthesizing a compound of formula (I), wherein R1 is C1-6alkoxy or haloC1-6alkoxy, R2 is C1-6alkyl unsubstituted or substituted by a substituent selected from C1-6alkoxy and haloC1-6alkoxy, R3 is C1-6alkyl,or pharmaceutically acceptable salts thereof, which is useful for prophylaxis and treatment of a viral disease in a patient relating to hepatitis B virus infection or a disease caused by hepatitis B virus infection.

NEW CRYSTALLINE FORMS OF (6S)-10-METHOXY-6-ISOPROPYL-9-(3-METHOXYPROPOXY)-2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID

The present invention relates to a new crystalline form of compound (I), (6S)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3- carboxylic acid and pharmaceutical compositions comprising the crystalline forms thereof disclosed herein, which may be used for the treatment or prophylaxis of a viral disease in a patient relating to hepatitis B infection or a disease caused by hepatitis B infection.

NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula (I) wherein R1 to R6, W and X are as described herein and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5 and Ar are as described herein, compositions including compounds and methods of using the compounds.

The development of a complementary pathway for the synthesis of aliskiren

The synthesis of aliskiren (1), a recently marketed drug for the treatment of hypertension, is presented. The focus of our synthetic effort is to develop an efficient pathway for the synthesis of (2S,7R,E)-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy) benzyl)-N,N,8-trimethylnon-4-enamide (2a), which has been used as the advanced intermediate toward aliskiren. After an extensive investigation of three different strategies designed to construct the E-olefin functionality in 2a by employing the olefin cross-metathesis, Horner-Wadsworth-Emmons (HWE), and Julia-type olefinations, we have established a new protocol for the synthesis of 2a with a substantially improved overall efficiency in terms of the yield (ca. 33%), and diastereo- and E/Z-selectivity. The key transformations were the Evans chiral auxiliary-aided asymmetric allylation for the synthesis of the appropriate chiral intermediates in excellent enantiomeric purity of higher than 97% ee and a modified Julia-Kocienski olefination for the highly selective construction of E-2a with up to 13.6:1 E/Z ratio from the chiral intermediates. Consequently, the results provide an appealing option for the synthesis of aliskiren. This journal is